Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib(328 views) Marotta V, Di Somma C, Rubino M, Sciammarella C, Modica R, Camera L, Del Prete M, Marciello F, Ramundo V, Circelli L, Buonomano P, Colao A, Faggiano A
Keywords: Sorafenib, Sunitinib, Adult, Adverse Outcome, Case Report, Clinical Feature, Diarrhea, Differentiated Thyroid Cancer, Drug Substitution, Drug Treatment Failure, Drug Withdrawal, Female, Hand Foot Syndrome, Human, Letter, Lung Metastasis, Lymph Node Metastasis, Middle Aged, Outcome Assessment, Priority Journal, Progression Free Survival, Treatment Response, Tumor Necrosis, Tumor Volume,
Affiliations: *** IBB - CNR ***
Department of Clinical Medicine and Surgery, Section of Endocrinology, Federico II University of Naples, Via S. Pansini 5, Naples, Italy
IRCCS SDN, Naples, Italy
Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy
National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy
References: Marotta, V., Sciammarella, C., Vitale, M., Colao, A., Faggiano, A., The evolving field of kinase inhibitors in thyroid cancer (2014) Crit. Rev. Oncol. Hematol., , PID: 2524082
Ho, A.L., Moving toward a better understanding of radioiodine action (2013) Endocrine, 44 (3), pp. 553-554. , COI: 1:CAS:528:DC%2BC3sXhtlGmu7bI, PID: 23990267
Marotta, V., Franzese, M.D., Del Prete, M., Chiofalo, M.G., Ramundo, V., Esposito, R., Marciello, F., Faggiano, A., Targeted therapy with kinase inhibitors in aggressive endocrine tumors (2013) Expert Opin. Pharmacother., 14 (9), pp. 1187-1203. , COI: 1:CAS:528:DC%2BC3sXnvV2ksLo%3D, PID: 23675883
Kloos, R.T., Ringel, M.D., Knopp, M.V., Hall, N.C., King, M., Stevens, R., Liang, J., Shah, M.H., Phase II trial of sorafenib in metastatic thyroid cancer (2009) J. Clin. Oncol., 27 (10), pp. 1675-1684. , COI: 1:CAS:528:DC%2BD1MXltVOht7g%3D, PID: 19255327
Marotta, V., Ramundo, V., Camera, L., Prete, M.D., Fonti, R., Esposito, R., Palmieri, G., Faggiano, A., Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET (2012) Clin Endocrinol (Oxf)
Gupta-Abramson, V., Troxel, A.B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S.J., Brose, M.S., Phase II trial of sorafenib in advanced thyroid cancer (2008) J. Clin. Oncol., 26 (29), pp. 4714-4719. , COI: 1:CAS:528:DC%2BD1cXhtlSqsb7M, PID: 18541894
Cabanillas, M.E., Waguespack, S.G., Bronstein, Y., Williams, M.D., Feng, L., Hernandez, M., Lopez, A., Busaidy, N.L., Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience (2010) J. Clin. Endocrinol. Metab., 95 (6), pp. 2588-2595. , COI: 1:CAS:528:DC%2BC3cXnvVaksr4%3D, PID: 20392874
Hoftijzer, H., Heemstra, K.A., Morreau, H., Stokkel, M.P., Corssmit, E.P., Gelderblom, H., Weijers, K., Smit, J.W., Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma (2009) Eur. J. Endocrinol., 161 (6), pp. 923-931. , COI: 1:CAS:528:DC%2BD1MXhsFOgt7rN, PID: 19773371
Brose, M.S., Nutting, C.M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Schlumberger, M.J., Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial (2014) Lancet
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Raymond, E., Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer (2006) J. Clin. Oncol., 24 (1), pp. 25-35. , COI: 1:CAS:528:DC%2BD28Xot1ChtQ%3D%3D, PID: 16314617
Carr, L.L., Mankoff, D.A., Goulart, B.H., Eaton, K.D., Capell, P.T., Kell, E.M., Bauman, J.E., Martins, R.G., Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation (2010) Clin. Cancer Res., 16 (21), pp. 5260-5268. , COI: 1:CAS:528:DC%2BC3cXhtl2rsLrF, PID: 20847059
Diez, J.J., Iglesias, P., Alonso, T., Grande, E., Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice (2014) Endocrine
E.E. Cohen, B.M. Needles, K. J.Cullen, S. J.Wong, J. L.Wade III, S. P.Ivy, V. M.Villaflor, T. Y.Seiwert, K.Nichols, E. E.Vokes: Phase 2 study of sunitinib in refractory thyroid cancer. J Clini Oncol, ASCO Annual Meeting ProceedingsKaldrymides, P., Kostoglou-Athanassiou, I., Gkountouvas, A., Veniou, E., Ziras, N., Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature (2010) Endocrine, 37 (1), pp. 6-10. , COI: 1:CAS:528:DC%2BC3cXpsFGqtw%3D%3D, PID: 20963554
Hutson, T.E., Bukowski, R.M., Cowey, C.L., Figlin, R., Escudier, B., Sternberg, C.N., Sequential use of targeted agents in the treatment of renal cell carcinoma (2011) Crit. Rev. Oncol. Hematol., 77 (1), pp. 48-62. , PID: 20705477
Xing, M., Haugen, B.R., Schlumberger, M., Progress in molecular-based management of differentiated thyroid cancer (2013) Lancet, 381 (9871), pp. 1058-1069. , COI: 1:CAS:528:DC%2BC3sXksFamsrk%3D, PID: 23668556
Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., Dancey, J., Verweij, J., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) (2009) Eur. J. Cancer, 45 (2), pp. 228-247. , COI: 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D, PID: 19097774
Dadu, R., Devine, C., Hernandez, M., Waguespack, S.G., Busaidy, N.L., Hu, M.I., Jimenez, C., Cabanillas, M.E., Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib (2014) J. Clin. Endocrinol. Metab., 99 (6), pp. 2086-2094. , COI: 1:CAS:528:DC%2BC2cXps12rtL8%3D, PID: 24628550
Faivre, S., Zappa, M., Vilgrain, V., Boucher, E., Douillard, J.Y., Lim, H.Y., Kim, J.S., Raymond, E., Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib (2011) Clin. Cancer Res., 17 (13), pp. 4504-4512. , COI: 1:CAS:528:DC%2BC3MXos1Smtb8%3D, PID: 21531821
Mizukami, Y., Kohgo, Y., Chung, D.C., Hypoxia inducible factor-1 independent pathways in tumor angiogenesis (2007) Clin. Cancer Res., 13 (19), pp. 5670-5674. , COI: 1:CAS:528:DC%2BD2sXhtFSntLzL, PID: 17908955
Chen, H.X., Cleck, J.N., Adverse effects of anticancer agents that target the VEGF pathway (2009) Nat Rev Clin Oncol, 6 (8), pp. 465-477. , COI: 1:CAS:528:DC%2BD1MXpsFyhsbY%3D, PID: 19581909
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib
Not available.
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib
No results.
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(498 views) Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 ViewExport to BibTeXExport to EndNote